Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
U B SchaadR Kraemer

Abstract

In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks. Fifty-six cases of acute pulmonary exacerbation of the disease in 42 patients associated with isolation of Pseudomonas aeruginosa from the sputum were randomly treated with either aztreonam or ceftazidime (300mg/kg/day i.v.; maximum daily dose 12g) in combination with amikacin (36mg/kg/day i.v.; maximum daily dose 1,500mg). Other aspects of the two-week treatment were constant. The two therapy groups were comparable in all respects. Both regimens were well tolerated and resulted in similar improvements in clinical, bacteriologic, radiologic and laboratory findings, and pulmonary function. Fifty patients could be reevaluated after subsequent outpatient therapy consisting of oral ciprofloxacin (30mg/kg/day; maximum daily dose 1,500mg) given for four weeks. During this period, the clinical and laboratory improvements persisted, and the rate of eradication of Pseudomonas aeruginosa from sputum decreased from 62% to 34%. Ciprofloxacin was well tolerated and there was no drug toxicity ...Continue Reading

References

Oct 1, 1985·Antimicrobial Agents and Chemotherapy·J S Wolfson, D C Hooper
Mar 1, 1988·The Pediatric Infectious Disease Journal·J A Bosso, P G Black
Jan 1, 1988·Reviews of Infectious Diseases·W ChristB Ulbrich
Jul 1, 1988·The Journal of Infectious Diseases·S SuterH P Schnebli
Oct 1, 1987·Clinical Pharmacokinetics·R de Groot, A L Smith
Jul 1, 1987·Thorax·A R PenkethJ C Batten
May 1, 1986·The Journal of Pediatrics·A L Smith
Apr 1, 1987·The Pediatric Infectious Disease Journal·J A BossoJ M Matsen
Oct 1, 1986·Antimicrobial Agents and Chemotherapy·M J SmithJ C Batten
Mar 1, 1984·The Journal of Pediatrics·R B MossN J Lewiston
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·N F AdkinsonA A Sugerman
Mar 1, 1983·The Journal of Pediatrics·R KraemerE Rossi
Nov 1, 1982·Antimicrobial Agents and Chemotherapy·N V JacobusM Barza
Dec 1, 1980·American Journal of Diseases of Children·R WientzenJ D Nelson
Jan 1, 1974·Pediatric Radiology·A R Chrispin, A P Norman

❮ Previous
Next ❯

Citations

Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M LeBel
Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·U B Schaad
Jan 1, 1997·The Pediatric Infectious Disease Journal·U B SchaadB Hampel
Dec 1, 2000·The Pediatric Infectious Disease Journal·E LeibovitzR Dagan
Oct 1, 1992·Journal of Clinical Pharmacy and Therapeutics·J A Bosso
May 1, 1992·Antimicrobial Agents and Chemotherapy·H PeltolaP J Neuvonen
Jul 26, 2011·Archives of Disease in Childhood·Abiodun AdefurinImti Choonara
Sep 13, 2012·Therapeutic Advances in Respiratory Disease·Matthew Hurley, Alan Smyth
Aug 1, 2015·The Cochrane Database of Systematic Reviews·Matthew N HurleyPatrick Flume
Dec 18, 2019·The Cochrane Database of Systematic Reviews·Sally PalserAlan R Smyth
Mar 1, 1994·The Annals of Pharmacotherapy·K A CampD J Schroeder
Nov 17, 2020·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Charlie McLeodThomas L Snelling

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.